Price range: €95.00 through €300.00

Retatrutide 10mg provides a compact research supply of the next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously, the most advanced incretin-based compound currently under metabolic study. Research has demonstrated superior weight reduction outcomes compared to dual-agonist peptides, with subjects showing significant reductions in body fat, improved insulin sensitivity, and favourable changes in lipid profiles. This 10mg vial suits shorter protocols or dose-finding studies. COA-backed with HPLC purity data. Lyophilised powder, requires reconstitution with bacteriostatic water.

Euro (€) - EUR
  • Euro (€) - EUR
  • Pound sterling (£) - GBP